Cardiovascular Drugs — MCQs

Cardiovascular Drugs Indian Medical PG Practice Questions and MCQs

Question 621: What is the drug of choice for managing an asthmatic patient with hypertension?

A. Timolol
B. Propranolol
C. Metoprolol
D. Amlodipine (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Amlodipine** **1. Why Amlodipine is the Drug of Choice:** In patients with **Bronchial Asthma**, the primary goal is to avoid any medication that can trigger bronchospasm. Amlodipine is a **Dihydropyridine Calcium Channel Blocker (CCB)**. It works by causing peripheral vasodilation without affecting the bronchial smooth muscle. Unlike beta-blockers, CCBs do not interfere with $\beta_2$ receptors in the lungs, making them safe and effective for hypertensive patients with co-existing respiratory diseases like asthma or COPD. **2. Why Other Options are Incorrect:** * **Propranolol (Option B):** This is a **non-selective beta-blocker**. It blocks both $\beta_1$ (heart) and $\beta_2$ (bronchioles) receptors. Blocking $\beta_2$ receptors leads to life-threatening bronchoconstriction in asthmatics. It is strictly contraindicated. * **Timolol (Option A):** Also a non-selective beta-blocker. Even when used as eye drops for glaucoma, systemic absorption can trigger severe asthma attacks. * **Metoprolol (Option C):** This is a **cardioselective ($\beta_1$) blocker**. While "safer" than propranolol, selectivity is dose-dependent and is lost at higher doses. In clinical practice and exams, even selective beta-blockers are generally avoided in asthmatics if safer alternatives like CCBs or ACE inhibitors are available. **3. NEET-PG High-Yield Pearls:** * **Preferred Antihypertensives in Asthma:** CCBs (Amlodipine), ACE inhibitors (though watch for "ACE-cough"), and ARBs (Losartan). * **Beta-blocker Contraindications:** Asthma, COPD, 2nd/3rd-degree heart block, and Prinzmetal angina. * **Drug of Choice for Hypertension with Diabetes:** ACE inhibitors (Renoprotective). * **Drug of Choice for Hypertension in Pregnancy:** Labetalol (followed by Methyldopa/Nifedipine).

Question 622: Losartan is:

A. ACE inhibitor
B. Angiotensin receptor blocker (Correct Answer)
C. Ca++ channel blocker
D. Ganglion blocker

Explanation: **Explanation:** **1. Why Option B is Correct:** Losartan is the prototype of the **Angiotensin II Receptor Blockers (ARBs)** [1]. It acts by selectively and competitively blocking the **AT1 receptors**, which are responsible for the major cardiovascular effects of Angiotensin II, such as vasoconstriction, aldosterone release, and sympathetic activation [1]. Unlike ACE inhibitors, ARBs do not inhibit the breakdown of bradykinin, making them a preferred alternative for patients who develop a dry cough [1], [2]. **2. Why Other Options are Incorrect:** * **Option A (ACE Inhibitors):** Drugs in this class (e.g., Enalapril, Lisinopril) inhibit the *Angiotensin-Converting Enzyme*. While they also reduce Angiotensin II levels, they increase bradykinin levels, often leading to a dry cough and angioedema [1], [2]. * **Option C (Ca++ Channel Blockers):** These drugs (e.g., Amlodipine, Verapamil) act by blocking L-type calcium channels in vascular smooth muscle or the myocardium to cause vasodilation or reduced cardiac contractility. * **Option D (Ganglion Blockers):** These are older drugs (e.g., Mecamylamine, Trimetaphan) that block nicotinic (Nn) receptors at autonomic ganglia. They are rarely used today due to extensive side effects. **3. High-Yield Clinical Pearls for NEET-PG:** * **Uricosuric Effect:** Losartan is unique among ARBs because it inhibits the URAT1 transporter, increasing uric acid excretion. This makes it the drug of choice for hypertensive patients with **Gout**. * **Teratogenicity:** Like ACE inhibitors, ARBs are **contraindicated in pregnancy** (Category D) as they cause fetal renal anomalies and skull hypoplasia [2]. * **Active Metabolite:** Losartan undergoes first-pass metabolism to form **EXP3174**, a carboxylic acid metabolite that is more potent and long-acting than the parent drug. * **Renoprotection:** ARBs are first-line for treating hypertension in patients with **Diabetic Nephropathy** as they reduce proteinuria.

Question 623: Long-term secondary prevention following myocardial infarction is recommended with which one of the following drug classes?

A. Antiplatelet drugs (Correct Answer)
B. Nitrates
C. Amiodarone
D. Calcium channel antagonists

Explanation: **Explanation:** **Why Antiplatelet drugs are correct:** Following a Myocardial Infarction (MI), the primary goal of secondary prevention is to prevent recurrent thrombotic events and stent thrombosis. **Antiplatelet therapy** (specifically Aspirin and P2Y12 inhibitors like Clopidogrel or Ticagrelor) is the cornerstone of this strategy. These drugs inhibit platelet aggregation, thereby preventing the formation of a white thrombus over a ruptured atherosclerotic plaque or within a coronary stent. Clinical trials have consistently shown that long-term antiplatelet therapy significantly reduces the risk of re-infarction and cardiovascular mortality. **Why the other options are incorrect:** * **Nitrates:** While excellent for acute symptomatic relief of angina (vasodilation), they do not improve long-term survival or prevent future MI. * **Amiodarone:** This is an anti-arrhythmic used for specific rhythm disturbances (like VT/VF). It is not used for routine secondary prevention due to its significant side-effect profile (pulmonary fibrosis, thyroid dysfunction) and lack of mortality benefit in post-MI patients without specific arrhythmias. * **Calcium Channel Antagonists (CCBs):** These are generally second-line agents. While they can be used for hypertension or angina, they do not offer the same robust secondary prevention benefits as Beta-blockers or ACE inhibitors. In fact, short-acting nifedipine is contraindicated post-MI. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Post-MI "Mnemonic" (BAAS):** **B**eta-blockers, **A**CE inhibitors (or ARBs), **A**ntiplatelets (DAPT), and **S**tatins. These four classes are proven to reduce mortality. * **DAPT Duration:** Dual Antiplatelet Therapy (DAPT) is typically recommended for **12 months** post-ACS, regardless of whether a stent was placed. * **Aspirin Dose:** Low-dose aspirin (75–150 mg) is continued indefinitely for life.

Question 624: Which of the following ACE inhibitors is NOT a prodrug?

A. Fosinopril
B. Enalapril
C. Ramipril
D. Lisinopril (Correct Answer)

Explanation: **Explanation:** Most Angiotensin-Converting Enzyme (ACE) inhibitors are **prodrugs**. They are administered in an inactive form and must undergo hepatic conversion (ester hydrolysis) into their active "at" metabolites (e.g., Enalapril to Enalaprilat) to exert their pharmacological effect. **Why Lisinopril is the correct answer:** **Lisinopril** and **Captopril** are the two primary exceptions to this rule. They are **not prodrugs**; they are pharmacologically active in their parent form and do not require hepatic metabolism for activation. This makes them particularly useful in patients with hepatic impairment. **Analysis of Incorrect Options:** * **A. Fosinopril:** A prodrug converted to fosinoprilat. It is unique because it undergoes "balanced" dual excretion (both renal and biliary), making it safer in renal failure. * **B. Enalapril:** A classic prodrug converted to enalaprilat. It is the most commonly used IV ACE inhibitor (in its active form, enalaprilat). * **C. Ramipril:** A prodrug converted to ramiprilat. It is highly lipophilic and frequently used for its cardioprotective benefits post-MI. **High-Yield Clinical Pearls for NEET-PG:** * **The "Pril" Exceptions:** Remember the mnemonic **"L-C"** (Lisinopril and Captopril) as the non-prodrugs. * **Pharmacokinetics:** Because Lisinopril is not metabolized by the liver and is excreted unchanged by the kidneys, its dose must be strictly adjusted in chronic kidney disease (CKD). * **Shortest Acting:** Captopril has the shortest half-life and requires multiple daily dosing. * **Longest Acting:** Ramipril and Lisinopril have longer half-lives, allowing for once-daily dosing.

Question 625: A 70-year-old man has isolated systolic hypertension. On examination, his blood pressure is 170/80 mmHg, and his heart and lungs are normal. He has no other medical conditions. For this patient, select the most appropriate medication to manage his high blood pressure.

A. Thiazides (Correct Answer)
B. Spironolactone
C. Clonidine
D. Prazosin

Explanation: ### Explanation **1. Why Thiazides are the Correct Choice:** Isolated Systolic Hypertension (ISH), defined as SBP ≥140 mmHg with DBP <90 mmHg, is common in elderly patients due to age-related arterial stiffness. Large-scale clinical trials (like SHEP and ALLHAT) have established **Thiazide-type diuretics** and **Long-acting Dihydropyridine Calcium Channel Blockers (CCBs)** as the first-line agents for ISH. Thiazides are preferred because they effectively reduce stroke risk, cardiovascular events, and mortality in this specific demographic. **2. Why the Other Options are Incorrect:** * **B. Spironolactone:** This is a potassium-sparing diuretic/aldosterone antagonist. It is generally used as an add-on therapy for resistant hypertension or in patients with heart failure (HFrEF). It is not a first-line agent for uncomplicated ISH. * **C. Clonidine:** A centrally acting alpha-2 agonist. It is associated with significant side effects like sedation, dry mouth, and the risk of rebound hypertension if discontinued abruptly. It is never a first-line choice for chronic hypertension management. * **D. Prazosin:** An alpha-1 blocker. While it can lower BP, it is primarily used in patients with concomitant Benign Prostatic Hyperplasia (BPH). It is associated with "first-dose hypotension" and is not recommended as monotherapy for hypertension. **3. NEET-PG High-Yield Pearls:** * **Definition of ISH:** SBP >140 and DBP <90 mmHg. * **First-line for Elderly/ISH:** Thiazides (e.g., Chlorthalidone) or CCBs (e.g., Amlodipine). * **Chlorthalidone vs. Hydrochlorothiazide:** Chlorthalidone is often preferred in exams/clinical practice due to its longer half-life and superior evidence in reducing CV events. * **Side Effects of Thiazides:** Hyper**G**lycemia, Hyper**L**ipidemia, Hyper**U**ricemia, and Hyper**C**alcemia (**GLUC**), but **Hypo**kalemia and **Hypo**natremia.

Question 626: The beneficial effects of nitrates in the treatment of angina include the following except?

A. Decreased arterial pressure
B. Decreased ventricular volume
C. Decreased diastole perfusion time (Correct Answer)
D. Decreased ejection time

Explanation: **Explanation:** Nitrates are primarily **venodilators** that reduce myocardial oxygen demand. The correct answer is **C (Decreased diastole perfusion time)** because this is actually a **detrimental** effect, not a beneficial one. 1. **Why Option C is correct (The "Except"):** Nitrates can cause reflex tachycardia (due to a drop in blood pressure). Since coronary arteries are perfused primarily during **diastole**, an increase in heart rate shortens the diastolic period. This decreases the time available for coronary perfusion, which is a potential adverse effect rather than a benefit. 2. **Why the other options are wrong (Beneficial effects):** * **A. Decreased arterial pressure:** At higher doses, nitrates cause arteriolar dilation, reducing afterload. This decreases the work the heart must do to pump blood, lowering oxygen demand. * **B. Decreased ventricular volume:** By increasing venous capacitance (venodilation), nitrates decrease venous return to the heart (preload). This reduces Left Ventricular End-Diastolic Volume (LVEDV), which decreases wall tension and oxygen consumption. * **C. Decreased ejection time:** By reducing preload and afterload, the heart spends less time in the systolic ejection phase, further reducing oxygen demand. **High-Yield NEET-PG Pearls:** * **Mechanism:** Nitrates are converted to **Nitric Oxide (NO)**, which stimulates **guanylyl cyclase**, increasing **cGMP** and leading to dephosphorylation of myosin light chains (smooth muscle relaxation). * **Nitrate Tolerance:** Continuous use leads to "tachyphylaxis" due to depletion of sulfhydryl groups. A "nitrate-free interval" (8–12 hours) is required daily. * **Monday Disease:** Workers in dynamite factories developed tolerance during the week but experienced headaches and tachycardia on Mondays (loss of tolerance over the weekend). * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can cause life-threatening hypotension.

Question 627: Acute symptomatic sinus bradycardia usually responds to which of the following medications?

A. Adrenaline
B. Dopamine
C. Atropine (Correct Answer)
D. Norepinephrine

Explanation: **Explanation:** **1. Why Atropine is Correct:** Atropine is the **first-line drug** for acute symptomatic bradycardia. It is a competitive **muscarinic antagonist** that blocks the action of acetylcholine at the M2 receptors in the Sinoatrial (SA) node. By inhibiting the parasympathetic (vagal) tone, it increases the firing rate of the SA node and enhances conduction through the Atrioventricular (AV) node, thereby increasing the heart rate. **2. Why Other Options are Incorrect:** * **Adrenaline (Epinephrine):** While it has potent $\beta_1$ agonist activity that increases heart rate, it is typically reserved for cardiac arrest or as a second-line infusion if atropine and pacing fail. * **Dopamine:** This is a second-line treatment option. It is used as an infusion for bradycardia associated with hypotension, but it is not the initial drug of choice. * **Norepinephrine:** It primarily acts on $\alpha_1$ receptors causing vasoconstriction. While it has some $\beta_1$ activity, the resulting increase in blood pressure often triggers a **reflex bradycardia**, making it unsuitable for treating slow heart rates. **3. NEET-PG High-Yield Pearls:** * **Standard Dose:** 0.5 mg IV every 3–5 minutes (Maximum total dose: 3 mg). * **Paradoxical Effect:** Doses of atropine **< 0.5 mg** can cause "paradoxical bradycardia" due to the blockade of presynaptic inhibitory M1 receptors on vagal nerve endings. * **Ineffectiveness:** Atropine is often ineffective in patients with **Heart Transplants** (denervated hearts) and **Type II Second-degree or Third-degree AV blocks** (where pacing is preferred). * **Drug of Choice for AV block in MI:** Atropine is specifically preferred for bradycardia/AV block occurring in **Inferior Wall MI** (due to high vagal tone).

Question 628: Which of the following antilipidemic drugs reduces cholesterol levels by decreasing cholesterol absorption in the intestine by acting on NPC1L1 receptors?

A. Fenofibrate (Correct Answer)
B. Nicotinic acid
C. Lovastatin
D. Ezetimibe

Explanation: **Explanation:** The question asks for the drug that inhibits cholesterol absorption via the **NPC1L1 (Niemann-Pick C1-Like 1)** protein. **Note on the Answer Key:** There appears to be a discrepancy in the provided key. **Ezetimibe (Option D)** is the classic and specific inhibitor of the NPC1L1 transporter. **Fenofibrate (Option A)** is a PPAR-α agonist and does not act on NPC1L1. **1. Why Ezetimibe is the correct mechanism-based answer:** Ezetimibe selectively inhibits the **NPC1L1 receptor** located on the brush border of enterocytes in the small intestine. This action blocks the absorption of both dietary and biliary cholesterol. By reducing the delivery of intestinal cholesterol to the liver, it upregulates LDL receptors, leading to a reduction in serum LDL-C levels. **2. Why the other options are incorrect:** * **Fenofibrate (Option A):** A Fibrate that activates **PPAR-α** (Peroxisome Proliferator-Activated Receptor-alpha). Its primary effect is to increase LPL (Lipoprotein Lipase) activity, significantly lowering triglycerides. * **Nicotinic Acid (Option B):** Inhibits the lipolysis of triglycerides in adipose tissue by acting on G-protein coupled receptors, thereby reducing VLDL and LDL synthesis. * **Lovastatin (Option C):** A Statin that competitively inhibits **HMG-CoA reductase**, the rate-limiting enzyme in hepatic cholesterol synthesis. **High-Yield NEET-PG Pearls:** * **Ezetimibe** is often used as an "add-on" to statin therapy (synergistic effect). * **NPC1L1** is the specific molecular target for Ezetimibe. * **Side Effects:** Ezetimibe is generally well-tolerated but may cause reversible hepatic impairment when combined with statins. * **Drug of Choice for Hypertriglyceridemia:** Fibrates (like Fenofibrate). * **Drug of Choice for Hypercholesterolemia:** Statins.

Question 629: What is the drug of choice for chronic heart failure?

A. ACE inhibitors (Correct Answer)
B. Beta-blockers
C. Digoxin
D. Spironolactone

Explanation: **Explanation:** The primary goal in managing **Chronic Heart Failure (CHF)** with reduced ejection fraction is to counteract the maladaptive neurohormonal activation (specifically the Renin-Angiotensin-Aldosterone System) that leads to cardiac remodeling and disease progression. **Why ACE Inhibitors are the Drug of Choice (DOC):** ACE inhibitors (e.g., Enalapril, Ramipril) are considered the first-line therapy because they are the first class of drugs proven to **reduce mortality** and morbidity in all stages of CHF. They decrease afterload (via vasodilation) and preload, but most importantly, they inhibit the trophic effects of Angiotensin II, thereby **preventing and reversing cardiac remodeling.** **Analysis of Other Options:** * **B. Beta-blockers:** While they also reduce mortality and are a cornerstone of therapy (e.g., Carvedilol, Metoprolol succinate), they are typically added once the patient is stable on an ACE inhibitor. They must be started at low doses to avoid acute decompensation. * **C. Digoxin:** It is a positive inotrope that improves symptoms and reduces hospitalization rates but has **no effect on mortality.** It is now reserved for patients with concomitant atrial fibrillation or those remaining symptomatic despite optimal therapy. * **D. Spironolactone:** This Mineralocorticoid Receptor Antagonist (MRA) reduces mortality in NYHA Class II-IV heart failure, but it is generally used as an **add-on therapy** to ACE inhibitors and Beta-blockers rather than a first-line monotherapy. **High-Yield Clinical Pearls for NEET-PG:** * **Mortality Benefit in CHF:** ACEIs, ARBs, Beta-blockers, MRAs (Spironolactone), and SGLT2 inhibitors (Dapagliflozin) all reduce mortality. * **ARNI (Sacubitril/Valsartan):** Currently preferred over ACEIs in many guidelines if the patient remains symptomatic, as it shows superior mortality reduction. * **Side Effect:** The most common reason for switching from an ACEI to an ARB is a **dry cough** (due to bradykinin accumulation).

Question 630: Which enzymes activate prodrugs of ACE inhibitors to their active form?

A. Amidases
B. Esterases (Correct Answer)
C. Angiotensin converting enzyme
D. Conjugases

Explanation: **Explanation:** Most ACE inhibitors (ACEIs) are formulated as **prodrugs** to improve their oral bioavailability and lipid solubility. These prodrugs are esters that require metabolic activation to become pharmacologically active. **1. Why Esterases are correct:** The conversion of an ACE inhibitor prodrug (e.g., Enalapril) into its active metabolite (e.g., Enalaprilat) occurs primarily in the **liver** via **hepatic esterases**. These enzymes hydrolyze the ester bond, releasing the active carboxylic acid form which can then bind to the Angiotensin Converting Enzyme. **2. Analysis of Incorrect Options:** * **Amidases:** These enzymes hydrolyze amide bonds. While important for the metabolism of drugs like Lidocaine, they are not involved in the activation of ACEI prodrugs. * **Angiotensin Converting Enzyme (ACE):** This is the *target* of the drug, not the activator. ACEIs inhibit this enzyme to prevent the conversion of Angiotensin I to Angiotensin II. * **Conjugases:** These are involved in Phase II metabolism (e.g., glucuronidation) to make drugs more water-soluble for excretion, rather than the initial activation of prodrugs. **High-Yield Clinical Pearls for NEET-PG:** * **The Exceptions:** All ACE inhibitors are prodrugs **EXCEPT Captopril and Lisinopril**. These two are already active and do not require hepatic activation (useful in patients with severe liver disease). * **Active Metabolites:** Enalapril → Enalaprilat; Ramipril → Ramiprilat; Perindopril → Perindoprilat. * **Excretion:** Most ACEIs are excreted renally. **Fosinopril** and **Moexipril** are unique as they have significant biliary excretion, making them safer in patients with renal impairment. * **Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased potassium, Leukopenia).

Practice by Chapter

Antihypertensive Agents

Practice Questions

Drugs for Heart Failure

Practice Questions

Antiarrhythmic Drugs

Practice Questions

Antianginal Agents

Practice Questions

Lipid-Lowering Drugs

Practice Questions

Anticoagulants and Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Drugs Used in Pulmonary Hypertension

Practice Questions

Drugs Used in Shock

Practice Questions

Cardiovascular Effects of Non-Cardiovascular Drugs

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free